A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Tuen Mun Hospital
Federation Francophone de Cancerologie Digestive
Nanjing Sanhome Pharmaceutical, Co., Ltd.
UNICANCER
Shanghai Zhongshan Hospital
Peking University
Eastern Hepatobiliary Surgery Hospital
Mirror Biologics, Inc.
Inova Health Care Services
Zhujiang Hospital
AbbVie
Assistance Publique - Hôpitaux de Paris
Shanghai Zhongshan Hospital
Zhejiang Cancer Hospital
The Clatterbridge Cancer Centre NHS Foundation Trust
Shanghai Zhongshan Hospital
Second Affiliated Hospital of Guangzhou Medical University
Sinocelltech Ltd.
Guangxi Medical University
Third Affiliated Hospital, Sun Yat-Sen University
Qilu Pharmaceutical Co., Ltd.
THERABIONIC INC.
Shanghai Junshi Bioscience Co., Ltd.
Shandong New Time Pharmaceutical Co., LTD
Zhongda Hospital
Zhongda Hospital
West China Hospital
Tata Memorial Hospital
Federation Francophone de Cancerologie Digestive
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Sun Yat-sen University
Chinese PLA General Hospital
Innovent Biologics (Suzhou) Co. Ltd.
Fudan University
Ivy Life Sciences, Co., Ltd
RenJi Hospital
Sun Yat-sen University
RenJi Hospital
Guangxi Medical University
Guangxi Medical University
Guangxi Medical University
Guangxi Medical University
Guangxi Medical University
Sun Yat-sen University
Qingdao Central Hospital
Asan Medical Center
Peking University Cancer Hospital & Institute
Taichung Veterans General Hospital
Eastern Hepatobiliary Surgery Hospital